Together, we have generated MHC class I-restricted tumor-specific CD4+ TCR-Ts that were capable of antitumor effector functions comparable to CD8+ TCR-Ts, such as secretion of inflammatory cytokines and direct lysis of target cells. This evidence concerns the gene CD8A and neoplasm.